

ATMI LIFESCIENCES AND ARTELIS SIGN TWO STRATEGIC ALLIANCE AGREEMENTS

Hoegaarden, Belgium — November 27, 2006 —ATMI LifeSciences and Brussels-based Artelis today jointly announced agreements to focus on the commercialization and distribution of Artelis' proprietary disposable mixing technology integrated with ATMI's proprietary film technology, and to jointly develop, test and manufacture single-use bioreactors/fermentors.

The agreements will leverage ATMI LifeSciences expertise in advanced ultra-clean film manufacturing and single-use mixing technology with Artelis' knowledge of the cell culture process, fermentation applications and disposable bioreactors to provide customers with higher performance in purity, precision and process efficiency in the manufacture of advanced biopharmaceuticals.

ATMI LifeSciences Managing Director, Mario Philips, said: "Our initial focus has been to establish our scalable contained powder and liquid single-use mixing technologies. Now, through our alliance with Artelis we are completing our single-use mixing product offering for scalable liquid-to-liquid mixing applications. Artelis' mixing technology is more advanced than the recirculation pump and magnetic mixer liquid-to-liquid mixing systems currently available in the marketplace. This enables us to have suitable mixing product offerings across all bioprocess applications for our customers."

"Signing such a commercial agreement with a multinational company like ATMI is a fantastic outcome for a one-year-old Belgian company and a significant achievement for the Artelis management team," said José Castillo, President of Artelis. "We have been able to demonstrate the unique competitive advantages of Artelis' mixing technology (patent pending) and our ability to execute on development and industrialization plans to deliver value to the biopharma industry. As both the founder of Artelis and a former executive of a large biopharma company, I am also pleased to share my vision of the future of this industry with a formidable player in the sector."

"I am also very excited about our Joint Development Agreement around disposable bioreactors and fermentors," added Philips. "The collaboration combines ATMI LifeSciences' expertise in vertically integrated ultra-clean film manufacturing and

single-use mixing technology with Artelis' advanced process expertise in cell culture and fermentation applications. The jointly developed bioreactors and fermentors will be tested and validated within Artelis' new cell culture facility.”

Hugues Bultot, CEO of Artelis said: “In addition to a worldwide Sales and Marketing agreement, ATMI offered Artelis a unique opportunity to leverage our process expertise in cell culture and fermentation applications with their own expertise in the development of advanced bioreactors, which we hope will be valued by our customers. This is the first international recognition for our “Contract Development Organization,” an innovative Business Unit that offers development expertise in disposables for cell culture to others in the industry.”

ABOUT ARTELIS

Known for its revolutionary products, Artelis develops disposable solutions for cell culture and provides the missing link to the plastic factory—the single-use bioreactor. For more information about Artelis, contact José Castillo at j.castillo@artelis.be or visit the company's website at www.artelis.be.

ABOUT ATMI LIFESCIENCES

ATMI has recently established a product line under an ATMI LifeSciences banner focused on biopharmaceutical applications with flexible, film-based packaging products ranging from single-use mixing and storage vessels to ultraclean sterile containers. ATMI LifeSciences is a source of manufacturing efficiency to its biopharma customers, providing single-use smart processing and packaging technology solutions that maximize product integrity. Further information can be found at <http://www.atmi-lifesciences.com>.

ATMI provides specialty materials and high-purity materials handling and delivery solutions to the worldwide semiconductor industry. For more information, please visit www.atmi.com.

-Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2006 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in

semiconductor industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing and commercializing new products; problems or delays in integrating acquired operations and businesses; and other factors described in ATMI's filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.

###

For more information contact:

Mario Philips
ATMI LifeSciences
Hoegaarden Belgium
Managing Director ATMI LifeSciences
+32.16.76.61.59
mphilips@atmi.com

Dean Hamilton
ATMI, Inc.
Director, Investor Relations & Corporate Communications
203.207.9349 Direct
203.794.1100 x4202
dhamilton@atmi.com

José Castillo
Artelis sa
Neder-Over-Hembeek
President Artelis
+32.2.264.23.01
j.castillo@artelis.be